Scilex Holding Company Capital Expenditures
Scilex Holding Company (SCLX) reported Capital Expenditures of $593.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-14
- Scilex Holding Company payments to acquire property, plant, and equipment for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Scilex Holding Company payments to acquire property, plant, and equipment for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Scilex Holding Company payments to acquire property, plant, and equipment for the quarter ending 2023-12-31 was $1.00K.
- Scilex Holding Company payments to acquire property, plant, and equipment for the quarter ending 2023-09-30 was $21.00K, a 200.00% increase year-over-year.
- Scilex Holding Company payments to acquire property, plant, and equipment for fiscal 2025 was $133.00K.
- Scilex Holding Company payments to acquire property, plant, and equipment for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Scilex Holding Company payments to acquire property, plant, and equipment for fiscal 2023 was $30.00K, a 328.57% increase from fiscal 2022.
- Scilex Holding Company payments to acquire property, plant, and equipment for fiscal 2022 was $7.00K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $593.00K 10-Q · filed 2026-08-14 | |||
| 2025-12-31 | $133.00K 10-K · filed 2026-04-10 | |||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-14 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $0.00 derived: sum of 2 quarters · filed 2026-04-10 | $0.00 10-K · filed 2026-04-10 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-01-17 | $0.00 10-Q · filed 2025-01-17 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-13 | |||
| 2023-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $22.00K derived: sum of 2 quarters · filed 2025-03-31 | $30.00K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-01-17 | $29.00K 10-Q · filed 2025-01-17 | ||
| 2023-06-30 | $8.00K 10-Q · filed 2024-08-13 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $7.00K derived: sum of 2 quarters · filed 2024-03-12 | $7.00K 10-K · filed 2024-03-12 | |
| 2022-09-30 | $7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $7.00K 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-11 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-03-12 | |||
| 2020-12-31 | $25.00K 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |